abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
36302: Infliximab Anti-drug Antibody For Rheumatic Diseases Print View
Infliximab ADA, Rheum ELISA    AU 
Interpretation      
Comment      

PRIMARY
1 Serum Red Top 1 (0.5) mL   Room Temperature - 48 Hour(s)/Refrigerated - 7 Day(s)/Frozen - 14 Day(s)  
ALTERNATE

When treatment of rheumatic diseases with infliximab fails, a physician may need to consider treatment options, such as adjusting dose or dosing intervals, switching to a different TNF blocker, or switching to a different drug agent, i.e. a non-TNF blocker. This assay specifically detects antibodies to infliximab that may reduce serum levels of the drug, as well as its clinical efficacy.

Patient Preparation: For up to 48 hours before blood draw, do not take
multivitamins or dietary supplements containing biotin or vitamin B7.
Fasting not required
Setup Schedule
Tuesday

Reported (Analytical Time)
2 days

CPT Code
83520

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
**This test is not available for New York patient testing**
Reject Criteria: Serum Separator Tube; gross hemolysis; grossly icteric
Transport Temperature: Refrigerated
Specimen Stability:
Frozen (-20 degrees Celsius): 14 days
Frozen (-70 degrees Celsius): 60 days
Methodology: Enzyme Linked Immunosorbent Assay






1996 - 2018 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database